GB8824709D0 - Oral dosage forms of omega-3 polyunsaturated acids - Google Patents

Oral dosage forms of omega-3 polyunsaturated acids

Info

Publication number
GB8824709D0
GB8824709D0 GB888824709A GB8824709A GB8824709D0 GB 8824709 D0 GB8824709 D0 GB 8824709D0 GB 888824709 A GB888824709 A GB 888824709A GB 8824709 A GB8824709 A GB 8824709A GB 8824709 D0 GB8824709 D0 GB 8824709D0
Authority
GB
United Kingdom
Prior art keywords
omega
dosage forms
oral dosage
polyunsaturated acids
polyunsaturated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB888824709A
Other versions
GB2223943A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tillotts Pharma AG
Original Assignee
Tillotts Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tillotts Pharma AG filed Critical Tillotts Pharma AG
Priority to GB8824709A priority Critical patent/GB2223943A/en
Publication of GB8824709D0 publication Critical patent/GB8824709D0/en
Priority to CA 2000881 priority patent/CA2000881A1/en
Priority to AU44856/89A priority patent/AU4485689A/en
Priority to PCT/GB1989/001251 priority patent/WO1990004391A1/en
Publication of GB2223943A publication Critical patent/GB2223943A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
GB8824709A 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids Withdrawn GB2223943A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
GB8824709A GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids
CA 2000881 CA2000881A1 (en) 1988-10-21 1989-10-17 Oral dosage forms of omega-3 polyunsaturated acids
AU44856/89A AU4485689A (en) 1988-10-21 1989-10-20 Oral dosage forms of omega-3 polyunsaturated acids
PCT/GB1989/001251 WO1990004391A1 (en) 1988-10-21 1989-10-20 Oral dosage forms of omega-3 polyunsaturated acids

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8824709A GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids

Publications (2)

Publication Number Publication Date
GB8824709D0 true GB8824709D0 (en) 1988-11-30
GB2223943A GB2223943A (en) 1990-04-25

Family

ID=10645593

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8824709A Withdrawn GB2223943A (en) 1988-10-21 1988-10-21 Oral disage forms of omega-3 polyunsaturated acids

Country Status (4)

Country Link
AU (1) AU4485689A (en)
CA (1) CA2000881A1 (en)
GB (1) GB2223943A (en)
WO (1) WO1990004391A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
US5457130A (en) * 1989-03-20 1995-10-10 Cancer Research Campaign Technology Limited Eicosapentaenoic acid used to treat cachexia
FR2663222A1 (en) * 1990-06-13 1991-12-20 Medgenix Group Sa OILY LIQUID MICROCAPSULE.
NZ241359A (en) * 1991-01-24 1994-08-26 Martek Corp Supplementation of infant formula by the addition of at least two different polyunsaturated fatty acids obtained from at least two different microbial sources; compositions comprising such oils
GB9509764D0 (en) * 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
GB2300807B (en) * 1995-05-15 1999-08-18 Tillotts Pharma Ag Oral dosage forms of omega-3 polynunsaturated acids for the treatment of inflammatory bowel disease
AU2623797A (en) * 1995-12-11 1997-07-03 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US5840715A (en) * 1995-12-11 1998-11-24 Inholtra Investment Holdings & Trading, N.V. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
US6797289B2 (en) 1998-02-13 2004-09-28 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US20070141181A1 (en) 1998-02-13 2007-06-21 Nutramax Laboratories, Inc. Use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals
US6451771B1 (en) 1999-02-12 2002-09-17 Nutramax Laboratories, Inc. Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
DE19930030B4 (en) * 1999-06-30 2004-02-19 Meduna Arzneimittel Gmbh Oral dosage form containing CO-3-unsaturated fatty acids
EP1407767A4 (en) * 2001-06-18 2007-01-24 Yamada Sachiko Pparg agonistic medicinal compositions
WO2003043570A2 (en) * 2001-11-15 2003-05-30 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
NZ569868A (en) * 2002-09-27 2010-01-29 Martek Biosciences Corp Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
WO2004078166A2 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
US7759507B2 (en) 2003-09-05 2010-07-20 Abbott Laboratories Lipid system and methods of use
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0428384D0 (en) * 2004-12-24 2005-02-02 Sla Pharma Ag Eicosapentaenoic acid
US20090214466A1 (en) * 2005-05-09 2009-08-27 Levin Bruce H Methods of Alleviating Disorders and Their Associated Pain
JP2009523414A (en) 2005-12-21 2009-06-25 ブルーディ、テクノロジー、ソシエダッド、リミターダ Use of DHA, EPA or DHA-derived EPA to treat lesions associated with oxidative damage of cells
ES2277557B1 (en) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. USE OF DOCOSAHEXAENOIC ACID FOR THE TREATMENT OF OXIDATIVE CELL DAMAGE.
JP5924834B2 (en) 2008-09-02 2016-05-25 アマリン ファーマシューティカルズ アイルランド リミテッド Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and method of using this pharmaceutical composition
SG172826A1 (en) * 2008-12-31 2011-08-29 Nitromega Corp Nutraceuticals containing nitro fatty acids
SG173612A1 (en) 2009-02-10 2011-09-29 Amarin Pharma Inc Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
RU2624506C2 (en) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Pharmaceutical compositions containing epa and cardiovascular agents and their application methods
CN102458109B (en) 2009-04-29 2015-02-11 阿马里纳制药公司 Stable pharmaceutical composition and methods of using same
PT2443246T (en) 2009-06-15 2018-03-14 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
BR122019016628B8 (en) 2009-09-23 2021-07-27 Amarin Corp Plc use of a composition comprising an atorvastatin hydroxy derivative or pharmaceutically acceptable salt thereof and an oil comprising ethyl eicosapentaenoate or ethyl docosahexaenoate for the manufacture of a medicament for the treatment of a cardiovascular disease
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (en) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド Compositions and methods for reducing the level of high sensitivity (HS-CRP) in a subject
HUE039659T2 (en) 2012-01-06 2019-01-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
TW201347754A (en) 2012-05-07 2013-12-01 Omthera Pharmaceuticals Inc Compositions of statins and omega-3 fatty acids
KR20150036252A (en) 2012-06-29 2015-04-07 애머린 파마슈티칼스 아일랜드 리미티드 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3135279A4 (en) * 2014-04-25 2018-01-03 Yamada Bee Company, Inc. Unsaturated fatty acid absorption accelerator
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10966951B2 (en) 2017-05-19 2021-04-06 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202102872QA (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5735512A (en) * 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
SE8604117D0 (en) * 1986-09-29 1986-09-29 Kabivitrum Ab COMPOSITION

Also Published As

Publication number Publication date
AU4485689A (en) 1990-05-14
GB2223943A (en) 1990-04-25
CA2000881A1 (en) 1990-04-21
WO1990004391A1 (en) 1990-05-03

Similar Documents

Publication Publication Date Title
GB8824709D0 (en) Oral dosage forms of omega-3 polyunsaturated acids
HU891084D0 (en) Process for manufacturing of pharmaceutical compositions containing antiviricid and antibactericid fatty acids and monoglycerides
HUP9900337A3 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
ZA895512B (en) Fatty acid composition
EP0334154A3 (en) Method for the continiuous esterification of fatty acids
IL78528A0 (en) Difluoro-naphthyridine-and trifluoro-quinoline-carboxylic acids and esters and salts thereof and pharmaceutical compositions containing them
ZA855264B (en) Bisphosphonic acids and pharmaceutically acceptable salts and esters thereof
NZ216971A (en) Phosphonate esters and pharmaceutical compositions
NZ215622A (en) Enhanced-absorption drug compositions containing fatty acids, monoglycerides and lysophosphatidyl choline
GB8812653D0 (en) Pharmaceutical composition based on high concentration esters of docosahexaenoic acid
IL78533A (en) Esters of 2-diazo-3-siloxyalkenoic acids and their preparation
GB2172597B (en) Polymerisation of fatty acids
IL85776A0 (en) Pharmaceutical compositions comprising certain algae and polyunsaturated fatty acids and their preparation
EP0227301A3 (en) Process for the preparation of n-formyl-alpha-l-aspartyl-l-phenylalanine methyl ester
ZA936233B (en) Method for the safe administration of fatty acids
ZA895758B (en) Polyunsaturated fatty acids
DE3660808D1 (en) Stabilized iodine fats and process for their preparation
ZA8614B (en) Basic formulations of quinolonecarboxylic acids
GB8506023D0 (en) Disproportionation of unsaturated acids
EP0226544A3 (en) Derivatives of alkyl-bicycloû2.2.1¨hept-5-ene-2-carboxylic acids
GB2183635B (en) Glyceride ester of gamma-linolenic acid
GB8712476D0 (en) Polyunsaturated fatty acids
GB2212048B (en) New unsaturated 3-benzylidenecamphor derivatives and their preparation
JPS6466144A (en) Manufacture of ketoprofen
GB8818735D0 (en) Preparation of unsaturated esters

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)